Intestinal Transport of Microbial Metabolites in Chronic Kidney Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-12-31

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic kidney disease is associated with the accumulation of various metabolites, i.e., uremic retention solutes. Evidence is mounting that the colonic microbiome contributes substantially to these uremic retention solutes. Indoxyl sulfate and p-cresyl sulfate are among the most extensively studied gut microbial metabolites, and are associated with cardiovascular disease, chronic kidney disease progression and overall mortality. Mechanisms governing their intestinal uptake and metabolism, however, are currently unknown. The investigators aim to explore these transport characteristics in depth. Therefore, colonic biopsies will be sampled of patients with chronic kidney disease, analyzed and compared to available data of healthy controls. Insights in the mechanisms controlling intestinal transport and metabolism of indoxyl sulfate and p-cresyl sulfate is certainly relevant as it might lead to novel therapeutic targets in the treatment of chronic kidney disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study on Colonic Fermentation in Chronic Kidney Disease Patients

NCT01874210

Renal Insufficiency, Chronic

COMPLETED

CKD Cachexia and Gut Microbiome

NCT06986265

Chronic Kidney Diseases Cachexia

RECRUITING

AXOS and Microbial Metabolites in CKD

NCT02141815

Chronic Kidney Disease

COMPLETED NA

The Role of P-cresol and Related Protein Fermentation Metabolites in Chronic Kidney Disease Patients

NCT00441623

Chronic Kidney Disease

COMPLETED

The Correlation Between Gut Microbiome/Metabolite and End Stage Renal Disease (ESRD)

NCT03010696

Kidney Failure, Chronic

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 and ≤ 85 years
* Chronic kidney disease ≤ stage III (KDOQI), i.e., estimated glomerular filtration rate (MDRD) \< 60 ml/min/m² or need of dialysis therapy 27
* Scheduled colonoscopy for diagnostic purposes
* Written informed consent

Exclusion Criteria

* History of gastro-intestinal disease (e.g., inflammatory bowel disease)
* History of colon surgery
* Recipient of a renal or other solid organ transplant
* Exposure to antibiotics or drug therapy with a known influence on intestinal transporters (e.g., P-gp) or enzymes during 2 weeks before colonoscopy

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No